Company
Bond Biosciences
Discovering and developing first-in-class non-absorbed oral therapeutics to prevent and treat ion-related human diseases
Also known as Bond Biosciences, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Bond Biosciences, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.
Funding snapshot
- Total raised
- $22.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series B2022-01-25
Funding rounds
- Round, 2026
- $7.6M2026-04-01, SEC form D sold, 83 investors
- Round, 2024
- $4.5M2024-08-22, SEC form D sold, 91 investors
- Round, 2021
- $6.8M2021-12-17, SEC form D sold, 81 investors
- Series A
- 2021-03-30
- Round, 2020
- $5M2020-10-23, SEC form D sold, 57 investors
- Round, 2020
- $200K2020-08-31, SEC form D sold, 8 investors
Products
- Other
- BBI-001
Loading relationship preview